--- schema_version: "secwatch.filing_event.v1" accession: "0001213900-23-058024" form_type: "8-K" ticker: "ESLA" cik: "0001844417" company_name: "Estrella Immunopharma, Inc." filed_at: "2023-07-19T23:59:59+00:00" generated_at: "2026-06-13T06:30:48.296763+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.55 calibrated_materiality_score: 0.55 confidence: "high" source: SEC EDGAR --- # TradeUP Acquisition Corp. extends business combination deadline to July 14, 2024 after stockholder vote ## Summary - Stockholders approved extension of deadline from July 19, 2023 to July 14, 2024 via charter and trust amendment. - 161,566 shares of common stock were redeemed in connection with the extension vote. - Monthly deposit of $0.05 per public share into trust account required during extension period. - Re-elected directors Tao Jiang and James as Class II directors for three-year term. - Ratified Marcum LLP as independent auditor for fiscal year ending December 31, 2023. ## SEC filing metadata - accession: 0001213900-23-058024 - form_type: 8-K - ticker: ESLA - cik: 0001844417 - company_name: Estrella Immunopharma, Inc. - filed_at: 2023-07-19T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.55 - calibrated_materiality_score: 0.55 - confidence: high - sec_items: 1.01, 5.03, 5.07, 8.01, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1844417/000121390023058024/0001213900-23-058024-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1844417/000121390023058024/ea181964-8k_tradeupacq.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001213900-23-058024 - JSON: https://secwatch.observer/filing/0001213900-23-058024.json - Plain text: https://secwatch.observer/filing/0001213900-23-058024.txt ## Key facts - Governance Changes Estrella Immunopharma, Inc.: Amended certificate of incorporation to extend business combination deadline from July 19, 2023 to July 14, 2024 (effective 2023-07-17). - Change: charter amendment - Effective: 2023-07-17 source text: the Company filed a certificate of amendment to the Charter which became effective upon filing evidence_url: https://www.sec.gov/Archives/edgar/data/1844417/000121390023058024/0001213900-23-058024-index.htm - Material Agreements Estrella Immunopharma, Inc. amended Investment Management Trust Agreement with Wilmington Trust, National Association valued at extend the liquidation date from July 19, 2023 to July 14, 2024 (effective 2023-07-17). - Action: amendment - Counterparty: Wilmington Trust, National Association - Value: extend the liquidation date from July 19, 2023 to July 14, 2024 - Effective: 2023-07-17 source text: On July 17, 2023, TradeUP Acquisition Corp. (the “Company”) held a special meeting in lieu of its 2023 annual meeting of stockholders (the “Special Meeting”), where the stockholders of the Company approved the Company to, among others, amend the Investment Management Trust Agreement dated July 14, 2021, as amended on December 29, 2022 (the “Trust Agreement”), by and between the Company and Wilmington Trust, National Association (the “Trustee”) to extend the liquidation date from July 19, 2023 to July 14, 2024. Upon the stockholders’ approval, on July 17, 2023, the Company and the Trustee entered into the amendment to the Trust Agreement. evidence_url: https://www.sec.gov/Archives/edgar/data/1844417/000121390023058024/0001213900-23-058024-index.htm - Shareholder Votes Estrella Immunopharma, Inc. shareholders approved Amend certificate of incorporation to extend business combination deadline at the 2023-07-17 meeting. - Proposal: charter amendment - Outcome: passed - Meeting: 2023-07-17 source text: The stockholders approved the proposal to amend the Company’s amended and restated certificate of incorporation to extend the date before which the Company must complete a business combination from July 19, 2023 to July 14, 2024 or such earlier date as determined by the board of directors of the Company (such extension is herein referred to as the “Extension”), and provide that the date for cessation of operations of the Company if the Company has not completed a business combination would similarly be extended (the “Extension Proposal”). Upon the stockholders’ approval, for each public share that is not redeemed by the stockholder in connection with the Extension, for each monthly period, or portion thereof during the Extension, the Company will deposit $0.05 per public share per month in the trust account. The voting results were as follows: FOR AGAINT ABSTAIN 1,908,849 6,306 0 evidence_url: https://www.sec.gov/Archives/edgar/data/1844417/000121390023058024/0001213900-23-058024-index.htm - Shareholder Votes Estrella Immunopharma, Inc. shareholders approved Election of Class II directors at the 2023-07-17 meeting. - Proposal: director election - Outcome: passed - Meeting: 2023-07-17 source text: The stockholders re-elected Mr. Tao Jiang and Mr. James as Class II directors of the Company to serve three-year term till the 2026 annual meeting of stockholders or until their successors are elected and qualified. The voting results were as follows: FOR WITHHOLD 1,906,559 8,596 evidence_url: https://www.sec.gov/Archives/edgar/data/1844417/000121390023058024/0001213900-23-058024-index.htm - Shareholder Votes Estrella Immunopharma, Inc. shareholders approved Amend Investment Management Trust Agreement to extend liquidation date at the 2023-07-17 meeting. - Outcome: passed - Meeting: 2023-07-17 source text: The stockholders approved the proposal to amend the Investment Management Trust Agreement, dated July 14, 2021, as amended on December 29, 2022, by and between the Company and Wilmington Trust, National Association, acting as trustee, to extend the liquidation date from July 19, 2023 to July 14, 2024 (the “Trust Amendment Proposal”). The voting results were as follows: FOR AGAINT ABSTAIN 1,908,849 6,306 0 evidence_url: https://www.sec.gov/Archives/edgar/data/1844417/000121390023058024/0001213900-23-058024-index.htm - Shareholder Votes Estrella Immunopharma, Inc. shareholders approved Ratification of Marcum LLP as auditor at the 2023-07-17 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2023-07-17 source text: The stockholders ratified the engagement of Marcum LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The voting results were as follows: FOR AGAINT ABSTAIN 2,055,472 105 0 evidence_url: https://www.sec.gov/Archives/edgar/data/1844417/000121390023058024/0001213900-23-058024-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.